ロード中...
Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment
BACKGROUND: Fingolimod (FTY) is the first oral medication approved for multiple sclerosis therapy. Until now, little has been known about the effects of FTY withdrawal regarding disease activity and development of tumefactive demyelinating lesions (TDLs), as already described in patients who discont...
保存先:
| 出版年: | Ther Adv Neurol Disord |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622113/ https://ncbi.nlm.nih.gov/pubmed/26557898 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285615594575 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|